PerkinElmer unveils COVID-19 rapid antigen test

By staff writers

February 23, 2021 -- PerkinElmer has launched a lateral-flow immunoassay COVID-19 antigen test, a rapid antigen test suitable for mass COVID-19 screening or for diagnosis of asymptomatic or symptomatic individuals.

The test can be used to detect SARS-CoV-2 nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens from asymptomatic or symptomatic individuals. Positive or negative results can be obtained in as little as 15 minutes, according to the company.

Available in more than 30 countries that accept the CE Mark, the IVD test is especially well-suited for point-of-care clinical and nonclinical settings such as healthcare centers, travel hubs, businesses, and educational institutions, the firm said. In clinical studies, the test yielded 97% sensitivity and 100% specificity across all samples.

FDA clears PerkinElmer coronavirus test for asymptomatic use
PerkinElmer's New Coronavirus Nucleic Acid Detection kit has received an emergency use authorization from the U.S. Food and Drug Administration (FDA)...
PerkinElmer to buy Oxford Immunotec Global
PerkinElmer plans to acquire Oxford Immunotec Global and that company's infectious disease testing technology in a deal worth $591 million. The purchase...
PerkinElmer receives CE Mark for SARS-CoV-2 assay
PerkinElmer has received a CE Mark for its SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) assay. Now, saliva can be designated...
PerkinElmer newborn screening test gets CE Mark
PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction newborn screening assay.
PerkinElmer debuts dried blood spot-based COVID-19 serology test
PerkinElmer has introduced a dry blood spot-based serology test for SARS-CoV-2 immunoglobulin G antibodies using its genetic screening processor/dissociation-enhanced...

Copyright © 2021

Last Updated ls 2/23/2021 5:29:57 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current